NCT02124044View on ClinicalTrials.gov

Safety, Tolerability, and Efficacy of Asunaprevir and Daclatasvir in Subjects Coinfected With HIV-HCV

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

March 31, 2016

Study Completion Date

November 30, 2016

Conditions
HIV-HCV
Interventions
DRUG

Asunaprevir and Daclatasvir

Oral treatment with Asunaprevir 100mg (ASV), twice daily, and Daclatasvir 60mg (DCV), once daily, for 24 weeks in HIV/HCV genotype 1b patients

DRUG

Asunaprevir and Daclatasvir with BMS-791325

Oral treatment with Asunaprevir 200mg (ASV), Daclatasvir 30 mg (DCV) and BMS-791325 75 mg in a fixed dose combination pill (FDC), twice daily, for 12 weeks in HIV/HCV genotype 1a or 1b patients

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

National Institutes of Health Clinical Center (CC)

NIH